Copper compounds in cancer chemotherapy.

Area of Science:

• Medicinal Inorganic Chemistry
• Coordination Chemistry
• Drug Discovery

Background:

• Transitional metals possess tunable properties (coordination numbers, redox states, reactivity) via ligand selection, offering advantages over organic drugs.
• Historically, platinum-based drugs dominated anticancer research; however, alternative metal compounds with novel mechanisms are needed.
• Copper complexes, particularly Casiopeinas, are gaining attention for their antitumoral potential and distinct cytotoxic profiles.

Purpose of the Study:

• To review current research on copper compounds as antitumoral agents.
• To highlight the potential of copper complexes, specifically the Casiopeina family, in cancer therapy.
• To explore alternative metal-based anticancer strategies beyond traditional platinum drugs.

Main Methods:

• Literature review of copper-based antitumoral compounds.
• Analysis of coordination chemistry principles applied to drug design.
• Examination of cytotoxic response profiles of copper complexes.

Main Results:

• Copper complexes exhibit diverse coordination and reactivity, enabling tailored drug development.
• Casiopeina compounds demonstrate significant antitumoral activity through mechanisms distinct from platinum agents.
• Ligand selection is crucial for optimizing the efficacy and safety of copper-based anticancer drugs.

Conclusions:

• Copper complexes represent a viable and promising class of anticancer agents.
• The Casiopeina family exemplifies the therapeutic potential of copper in oncology.
• Further research into metal-based drugs offers new strategies for overcoming cancer resistance and improving treatment outcomes.